fda announcement semaglutide Hims & Hers stock falls 25% as curtails compounded GLP-1s The FDA has approved a

Search Strategy and Study Selection This narrative review was conducted to summarize and critically appraise current evidence on the use of glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin agonists, and triple receptor agonists in the management of obesity, with a particular focus on adolescent populations

The theoretical advantage of combining both agents is targeting multiple metabolic pathways: berberine enhances cellular insulin sensitivity, while GLP-1 improves beta-cell function and reduces appetite

Whether weight loss can be maintained with lower doses after patients have sustained a stable reduced weight for several years remains to be determined

As well as having no significant effect on weight, being a laxative, psyllium husk may result in side-effects including diarrhoea and flatulence